## UPL Limited

## Agriculture

## Weak performance amidst industry headwinds; steep reduction in guidance

UPL reported a weak Q2FY24 primarily on channel destocking and higher pricing pressure. All segments reported revenue decline YoY. However, differentiated and sustainable product portfolio posted volume growth of $11 \%$ YoY. Also, the seed business recorded 10\% revenue growth YoY. Management indicated a relatively better H2FY24 primarily on (1) start of crop season in key operating regions, (2) reduction in high-cost inventory and (3) reduction in channel destocking. Also, management indicated volume growth to improve from Q4FY24. However, it has further reduced its overall annual guidance. We cut our earnings sharply to factor in subdued H1FY24, lower guidance and prevalent industry headwinds. Downgrade to HOLD (from Add) with a revised DCF-based TP of INR 562 (implied FY25 P/E: 13x; earlier TP: INR 673).

## Q2FY24 results

UPL reported revenue decline of 18.7\% YoY. EBITDA and PAT declined 42.8\% and $81.7 \%$, respectively YoY. EBITDA margin contracted 667bps YoY due to revenue decline and increase in staff costs. The revenue declined primarily on channel destocking and pricing pressure. Volumes and price realisations declined $7 \%$ and $15 \%$, respectively YoY.

## Likely revival in H2FY24

The company indicated a relatively better H2FY24 due to (1) key regions entering into major crop season, (2) exhaustion of most of the high-cost inventory, (3) normalising channel inventory and (4) likely revival in molecule prices. The company indicates that the prices are likely to remain subdued but volume growth is likely to be strong in H1FY25.

## Reduction in revenue and earnings guidance

The company has cut its FY24 revenue growth guidance from $+1-5 \%$ to flat, and EBITDA growth guidance from $+3-7 \%$ to flat to $-5 \%$. While the industrywide impact is likely to hurt UPL, we believe if the company is able to gain market shares, it will be DCF accretive.

## Valuation and risks

We downgrade the stock to HOLD due to weak H1FY24 results, revision in guidance and industry headwinds. Our revised DCF-based TP stands at INR 562 (implied FY25 P/E: 13x; earlier TP: INR 673). Key risks are higher competition and steep input inflation.

Financial Summary

| Y/E March (INR mn) | FY23A | FY24E | FY25E | FY26E |
| :--- | ---: | ---: | ---: | ---: |
| Net Revenue | $5,35,760$ | $4,65,414$ | $4,88,527$ | $5,12,833$ |
| EBITDA | $1,12,830$ | 83,309 | 99,660 | $1,07,695$ |
| EBITDA Margin (\%) | 21.1 | 17.9 | 20.4 | 21.0 |
| Net Profit | 45,140 | 21,697 | 32,971 | 38,395 |
| EPS (INR) | 59.0 | 28.4 | 43.1 | 50.2 |
| EPS \% Chg YoY | 6.7 | $(51.9)$ | 52.0 | 16.5 |
| P/E (x) | 9.1 | 19.0 | 12.5 | 10.7 |
| EV/EBITDA (x) | 5.1 | 6.6 | 5.2 | 4.4 |
| RoCE (\%) | 13.3 | 7.2 | 8.6 | 9.0 |
| RoE (\%) | 13.9 | 6.0 | 8.5 | 9.2 |

## Aniruddha Joshi

aniruddha.joshi@icicisecurities.com
+91 2268077249
Nilesh Patil
nilesh.patil@icicisecurities.com

Market Data

| Market Cap (INR) |  | 404bn |  |
| :--- | ---: | ---: | ---: |
| Market Cap (USD) |  | $4,857 \mathrm{mn}$ |  |
| Bloomberg Code |  | UPLL IN |  |
| Reuters Code |  | UPLL.BO |  |
| 52-week Range (INR) |  | $807 / 532$ |  |
| Free Float (\%) |  | 67.0 |  |
| ADTV-3M (mn) (USD) |  |  | 20.9 |
|  |  |  |  |
|  | Price Performance (\%) | $\mathbf{3 m}$ | $\mathbf{1 2 m}$ |
| Absolute | $(12.4)$ | $(26.0)$ | $(23.3)$ |
| Relative to Sensex | $(9.6)$ | $(32.0)$ | $(31.6)$ |
|  |  |  |  |
| ESG Disclosure | 2021 | 2022 | Change |
| ESG score | 63.6 | 64.8 |  |
| Environment | 52.5 | 54.5 | 1.3 |
| Social | 47.0 | 48.8 | 1.8 |
| Governance | 91.1 | 91.1 |  |

Note - Score ranges from 0-100 with a higher score indicating higher ESG disclosures.

Source: Bloomberg, I-sec research

| Earnings Revisions (\%) | FY24E | FY25E |
| :--- | ---: | ---: |
| Revenue | 0.0 | 0.0 |
| EBITDA | $(17.3)$ | $(6.2)$ |
| EPS | $(40.8)$ | $(15.6)$ |
|  |  |  |
| Previous Reports |  |  |
| 01-08-2023: Q1FY24 result review |  |  |
| 19-05-2023: Q4FY23 result review |  |  |

Exhibit 1: Q2FY24 financial performance

| Y/e March (INR mn) | Q2FY24 | Q2FY23 | YoY gr. | Q1FY24 | QoQ gr. |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Revenue | 1,01,700 | 1,25,070 | (18.7) | 89,630 | 13.5 |
| Expenditure |  |  |  |  |  |
| Raw materials | 52,320 | 57,810 | (9.5) | 39,300 | 33.1 |
| \% of revenue | 51.4 | 46.2 |  | 43.8 |  |
| Employee cost | 12,510 | 12,330 | 1.5 | 12,400 | 0.9 |
| \% of revenue | 12.3 | 9.9 |  | 13.8 |  |
| Other expenditure | 20,740 | 26,750 | (22.5) | 21,380 | (3.0) |
| \% of revenue | 20.4 | 21.4 |  | 23.9 |  |
| Total expenditure | 85,570 | 96,890 | (11.7) | 73,080 | 17.1 |
| EBITDA | 16,130 | 28,180 | (42.8) | 16,550 | (2.5) |
| EBITDA margin | 15.9 | 22.5 |  | 18.5 |  |
| Depreciation | 6,570 | 6,080 | 8.1 | 6,360 | 3.3 |
| EBIT | 9,560 | 22,100 | (56.7) | 10,190 | (6.2) |
| Interest Expenses | 8,710 | 6,440 | 35.2 | 7,000 | 24.4 |
| Other Income | 1,050 | 780 | 34.6 | 1,010 | 4.0 |
| Income from Associates | $(2,040)$ | (270) | - | (570) | - |
| Profit Before Tax | (140) | 16,170 | - | 3,630 | - |
| Income Taxes | (960) | 2,310 | (141.6) | $(1,640)$ | (41.5) |
| Profit After Tax | 820 | 13,860 | (94.1) | 5,270 | (84.4) |
| Pref. Dividend/ Minority Interest | $(1,300)$ | 2,260 | (157.5) | (810) | 60.5 |
| Net profit | 2,120 | 11,600 | (81.7) | 6,080 | (65.1) |
| Forex income/ cost | $(2,500)$ | $(3,240)$ |  | $(3,190)$ |  |
| Extraordinary Expenses | $(2,370)$ | 1,840 |  | $(1,770)$ |  |
| Profit for Shareholders | $(2,750)$ | 10,200 | - | 1,120 | - |

Source: Company data, I-Sec research

## Key performance highlights

Exhibit 2: Revenues and revenue growth


[^0]Exhibit 3: EBITDA and PAT margin


[^1]Exhibit 4: Q2FY24 Segment-wise financial performance

| INR mn | Q2FY24 | Q2FY23 | YoY Growth (\%) | Q1FY24 | QoQ Growth (\%) |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Revenues |  |  |  |  |  |
| Agro activity | 97,150 | 1,18,890 | -18.3\% | 84,450 | 15.0\% |
| Non Agro activity | 5,390 | 7,140 | -24.5\% | 6,250 | -13.8\% |
| Others/ Unallocated | (840) | (960) | -12.5\% | $(1,070)$ | -21.5\% |
| Total | 1,01,700 | 1,25,070 | -18.7\% | 89,630 | 13.5\% |
| EBIT |  |  |  |  |  |
| Agro activity | 8,980 | 20,180 | -55.5\% | 8,440 | 6.4\% |
| Non Agro activity | 630 | 1,250 | -49.6\% | 870 | -27.6\% |
| Others/ Unallocated | - | - | - | - | - |
| Total | 9,610 | 21,430 | -55.2\% | 9,310 | 3.2\% |
| EBIT margin (\%) |  |  |  |  |  |
| Agro activity | 9.2\% | 17.0\% |  | 10.0\% |  |
| Non Agro activity | 11.7\% | 17.5\% |  | 13.9\% |  |
| Others/ Unallocated | 0.0\% | 0.0\% |  | 0.0\% |  |
| Total | 9.4\% | 17.1\% |  | 10.3\% |  |

Source: Company data, I-Sec research

Exhibit 5: Revenue growth rate* by region - Q2FY24


Exhibit 6: Revenue growth breakup - Q2FY24


[^2]
## Q2FY24 results and conference call highlights

- Q2FY24 update: Q2FY24 was impacted by (1) channel destocking and (2) price decline across the regions. Also, unfavourable weather conditions in India and some parts of Asia weighed on performance.
- Volume and value growth: The company registered de-growth on 3 key parameters: (1) Volume: $-7 \%$; (2) Price: $-15 \%$ and currency exchange: $+3 \%$ YoY International business registered volume growth driven by high-margin sustainable products.
- Working Capital: NWC days increased by 25 days YoY to 149 days in Q2FY24. The reduction in payable days primarily led to an increase in NWC days. The management indicated it to normalize in H2FY24 and to be in line with last year.
- Guidance: The management revised revenue guidance lower to flattish growth YoY (earlier: in the 1-5\% range YoY). Also, EBITDA is likely to remain flat or post $5 \%$ de-growth YoY (earlier: in the $3-7 \%$ range YoY).

The management indicated relatively better H2FY24 against H1FY24 on improved performance in North America, LATAM and Europe (likely to enter into Crop season). The company indicated that strong volume growth is likely in Q4FY24 but pricing is likely to remain under pressure.

- Debt update: Net debt increased by USD 197 mn in Q2FY24 on account of a decline in factoring and higher working capital (lower payable days).

The company aims to reduce gross debt by USD 500mn by FY24 over FY23 positioning. The key triggers for the same are (1) slowing down capex and (2) likely better cash generation in H2FY24.

Factoring is likely to be at a similar level of USD 1.4bn. Interest cost on borrowings has increased. The benchmark rate rose by 200bps. The average cost of borrowing stood at 7\% per annum.

- Glyphosate update: The selling prices of the product have come down significantly YoY. However, the cost has been reduced. Thus, there is limited impact. The company has adjusted the prices corresponding to market prices. The company expects a moderate volume increase in H2FY24.

It indicated that overall FY24 is challenging for the product but FY25 onwards growth is likely to resume.

## Key financial charts (consolidated)

Exhibit 7: Revenues and growth rates


Source: Company data, I-Sec research

Exhibit 9: Net profit and growth rates


Source: Company data, I-Sec research

Exhibit 11: Net working capital days


Exhibit 8: EBITDA margin


Source: Company data, I-Sec research

Exhibit 10: Return ratios


Source: Company data, I-Sec research

Exhibit 12: OCF/EBITDA


## Valuation and risks

We value the stock on DCF basis with a revised target price of INR 562. At this target price, implied P/E works out to $13 x$ FY25E EPS. Downgrade to HOLD from ADD earlier.

Exhibit 13: DCF-based valuation

| Particulars | Amt (INR) |
| :--- | ---: |
| Cost of Equity (\%) | $12.6 \%$ |
| Terminal growth rate (\%) | $3.0 \%$ |
| Discounted interim cash flows (INR mn) | $2,59,474$ |
| Discounted terminal value (INR mn) | $1,70,318$ |
| Total equity value (INR mn) | $4,29,792$ |
| Value per share (INR) | 562 |

Source: I-Sec research
Risks
Lower-than-expected offtake of new products
Any failure of new products may impact our estimates.
Sharp increase in input prices and competition
Any major increase in commodity prices and/or competitive pressures could impact our earnings estimates.

Exhibit 14: Shareholding pattern

| \% | Mar'23 | Jun'23 | Sep'23 |
| :--- | ---: | ---: | ---: |
| Promoters | 32.4 | 32.4 | 32.4 |
| Institutional investors | 57.0 | 57.2 | 54.9 |
| MFs and others | 5.4 | 5.4 | 7.6 |
| FIs/Insurance | 8.4 | 8.6 | 8.7 |
| FIls | 43.2 | 43.2 | 38.6 |
| Others | 10.6 | 10.4 | 12.7 |

Exhibit 15: Price chart


[^3]Financial Summary
Exhibit 16: Profit \& Loss
(INR mn, year ending March)

|  | FY23A | FY24E | FY25E | FY26E |
| :---: | :---: | :---: | :---: | :---: |
| Net Sales | 5,35,760 | 4,65,414 | 4,88,527 | 5,12,833 |
| Operating Expenses | 4,22,930 | 3,82,105 | 3,88,868 | 4,05,138 |
| EBITDA | 1,12,830 | 83,309 | 99,660 | 1,07,695 |
| EBITDA Margin (\%) | 21.1 | 17.9 | 20.4 | 21.0 |
| Depreciation \& Amortization | 25,470 | 30,025 | 33,232 | 35,392 |
| EBIT | 87,360 | 53,284 | 66,428 | 72,303 |
| Interest expenditure | 29,630 | 23,174 | 22,965 | 22,756 |
| Other Non-operating Income | 4,770 | 1,850 | 2,331 | 2,902 |
| Recurring PBT | 62,500 | 31,960 | 45,793 | 52,448 |
| Profit / (Loss) from Associates | $(1,570)$ | (150) | (150) | (150) |
| Less: Taxes | 7,360 | 5,913 | 8,472 | 9,703 |
| PAT | 55,140 | 26,047 | 37,321 | 42,745 |
| Less: Minority Interest | 11,570 | 4,500 | 4,500 | 4,500 |
| Extraordinaries (Net) | 7,530 | - | - | - |
| Net Income (Reported) | 52,670 | 21,697 | 32,971 | 38,395 |
| Net Income (Adjusted) | 45,140 | 21,697 | 32,971 | 38,395 |

Source Company data, I-Sec research
Exhibit 17: Balance sheet
(INR mn, year ending March)

|  | FY23A | FY24E | FY25E | FY26E |
| :--- | ---: | ---: | ---: | ---: |
| Total Current Assets | $4,19,820$ | $3,87,006$ | $4,15,423$ | $4,51,997$ |
| of which cash \& cash eqv. | 60,970 | 69,998 | 83,547 | $1,04,538$ |
| Total Current Liabilities \& | $2,61,820$ | $2,23,399$ | $2,34,493$ | $2,46,160$ |
| Provisions | $1,58,000$ | $\mathbf{1 , 6 3 , 6 0 7}$ | $\mathbf{1 , 8 0 , 9 3 0}$ | $2,05,838$ |
| Net Current Assets | 24,030 | 39,030 | 54,030 | 69,030 |
| Investments | $1,88,150$ | $2,11,305$ | $2,05,073$ | $1,96,681$ |
| Net Fixed Assets | - | - | - | - |
| ROU Assets | 28,180 | - | - | - |
| Capital Work-in-Progress | $1,98,980$ | $1,98,980$ | $1,98,980$ | $1,98,980$ |
| Total Intangible Assets | - | - | - | - |
| Other assets | - | - | - | - |
| Deferred Tax assets | $5,97,340$ | $\mathbf{6 , 1 2 , 9 2 2}$ | $\mathbf{6 , 3 9 , 0 1 4}$ | $\mathbf{6 , 7 0 , 5 2 9}$ |
| Total Assets | $\mathbf{2 , 4 5 , 0 4 0}$ | $\mathbf{2 , 4 2 , 8 4 0}$ | $\mathbf{2 , 4 0 , 6 4 0}$ | $\mathbf{2 , 3 8 , 4 4 0}$ |
| Liabilities | $\mathbf{1 , 9 9 0 )}$ | $\mathbf{( 1 , 9 9 0 )}$ | $\mathbf{( 1 , 9 9 0 )}$ | $\mathbf{1 , 9 9 0 )}$ |
| Borrowings | - | - | - | - |
| Deferred Tax Liability | - | - | - | - |
| provisions | 1,500 | 1,500 | 1,500 | 1,500 |
| other Liabilities | $2,96,940$ | $3,10,222$ | $3,34,014$ | $3,63,229$ |
| Equity Share Capital | $\mathbf{2 , 9 8 , 4 4 0}$ | $\mathbf{3 , 1 1 , 7 2 2}$ | $\mathbf{3 , 3 5 , 5 1 4}$ | $\mathbf{3 , 6 4 , 7 2 9}$ |
| Reserves \& Surplus | 55,850 | 60,350 | 64,850 | 69,350 |
| Total Net Worth | $5,97,340$ | $\mathbf{6 , 1 2 , 9 2 2}$ | $\mathbf{6 , 3 9 , 0 1 4}$ | $\mathbf{6 , 7 0 , 5 2 9}$ |
| Minority Interest |  |  |  |  |
| Total Liabilities |  |  |  |  |

Source Company data, I-Sec research
Exhibit 18: Quarterly trend
(INR mn, year ending March)

|  | Dec-22 | Mar-23 | Jun-23 | Sep-23 |
| :--- | ---: | ---: | ---: | ---: |
| Net Sales | $1,36,790$ | $1,65,690$ | 89,630 | $1,01,700$ |
| \% growth (YOY) | 21.1 | 4.5 | $(17.2)$ | $(18.7)$ |
| EBITDA | 30,420 | 30,470 | 16,550 | 16,130 |
| Margin \% | 22.2 | 18.4 | 18.5 | 15.9 |
| Other Income | 1,150 | 2,110 | 1,010 | 1,050 |
| Extraordinaries | 10,780 | $(1,580)$ | $(1,770)$ | $(2,370)$ |
| Adjusted Net Profit | 21,090 | 7,120 | 1,120 | $(2,750)$ |

[^4]Exhibit 19: Cashflow statement
(INR mn, year ending March)

|  | FY23A | FY24E | FY25E | FY26E |
| :--- | ---: | ---: | ---: | ---: |
| Operating Cashflow | 56,200 | 59,643 | 66,930 | 74,371 |
| Working Capital Changes | $(13,690)$ | 3,420 | $(3,774)$ | $(3,917)$ |
| Capital Commitments | $(23,600)$ | $(25,000)$ | $(27,000)$ | $(27,000)$ |
| Free Cashflow | 32,600 | 34,643 | 39,930 | 47,371 |
| Other investing cashflow | 27,160 | $(15,000)$ | $(15,000)$ | $(15,000)$ |
| Cashflow from Investing | 3,560 | $(40,000)$ | $(42,000)$ | $(42,000)$ |
| Activities | $(13,550)$ | - | - | - |
| Issue of Share Capital | - | - | - | - |
| Interest Cost | $(36,290)$ | $(2,200)$ | $(2,200)$ | $(2,200)$ |
| Inc (Dec) in Borrowings | $(7,500)$ | $(8,415)$ | $(9,180)$ | $(9,180)$ |
| Dividend paid | - | - | - | - |
| Others | $(57,340)$ | $(10,615)$ | $(11,380)$ | $(11,380)$ |
| Cash flow from Financing |  |  |  |  |
| Activities | 2,420 | 9,028 | 13,550 | 20,991 |
| Chg. in Cash \& Bank | 61,370 | 79,025 | 97,097 | $1,25,528$ |
| balance |  |  |  |  |

## Exhibit 20: Key ratios

(Year ending March)

|  | FY23A | FY24E | FY25E | FY26E |
| :---: | :---: | :---: | :---: | :---: |
| Per Share Data (INR) |  |  |  |  |
| Reported EPS | 59.0 | 28.4 | 43.1 | 50.2 |
| Adjusted EPS (Diluted) | 59.0 | 28.4 | 43.1 | 50.2 |
| Cash EPS | 92.3 | 67.6 | 86.5 | 96.5 |
| Dividend per share (DPS) | 9.8 | 11.0 | 12.0 | 12.0 |
| Book Value per share (BV) | 390.1 | 407.5 | 438.6 | 476.8 |
| Dividend Payout (\%) | 16.6 | 38.8 | 27.8 | 23.9 |
| Growth (\%) |  |  |  |  |
| Net Sales | 15.9 | (13.1) | 5.0 | 5.0 |
| EBITDA | 11.2 | (26.2) | 19.6 | 8.1 |
| EPS (INR) | 6.7 | (51.9) | 52.0 | 16.5 |
| Valuation Ratios (x) |  |  |  |  |
| P/E | 9.1 | 19.0 | 12.5 | 10.7 |
| P/CEPS | 5.8 | 8.0 | 6.2 | 5.6 |
| P/BV | 1.4 | 1.3 | 1.2 | 1.1 |
| EV/EBITDA | 5.1 | 6.6 | 5.2 | 4.4 |
| P/ Sales | 0.8 | 0.9 | 0.8 | 0.8 |
| Dividend Yield (\%) | 1.8 | 2.0 | 2.2 | 2.2 |
| Operating Ratios |  |  |  |  |
| Gross Profit Margins (\%) | 49.1 | 46.5 | 49.0 | 49.6 |
| EBITDA Margins (\%) | 21.1 | 17.9 | 20.4 | 21.0 |
| Effective Tax Rate (\%) | 11.8 | 18.5 | 18.5 | 18.5 |
| Net Profit Margins (\%) | 8.4 | 4.7 | 6.7 | 7.5 |
| NWC / Total Assets (\%) | 16.2 | 15.3 | 15.2 | 15.1 |
| Net Debt / Equity (x) | 0.5 | 0.4 | 0.3 | 0.1 |
| Net Debt / EBITDA (x) | 1.4 | 1.6 | 1.0 | 0.6 |
| Profitability Ratios |  |  |  |  |
| RoCE (\%) | 13.3 | 7.2 | 8.6 | 9.0 |
| RoE (\%) | 13.9 | 6.0 | 8.5 | 9.2 |
| RolC (\%) | 13.3 | 7.2 | 8.6 | 9.0 |
| Fixed Asset Turnover (x) | 1.6 | 1.2 | 1.2 | 1.2 |
| Inventory Turnover Days | 102.3 | 88.2 | 97.2 | 97.2 |
| Receivables Days | 133.3 | 115.4 | 127.1 | 127.1 |
| Payables Days | 187.8 | 159.5 | 175.7 | 175.7 |

Source Company data, I-Sec research

This report may be distributed in Singapore by ICICI Securities, Inc. (Singapore branch). Any recipients of this report in Singapore should contact ICICI Securities, Inc. (Singapore branch) in respect of any matters arising from, or in connection with, this report. The contact details of ICICI Securities, Inc. (Singapore branch) are as follows: Address: 10 Collyer Quay, \#40-92 Ocean Financial Tower, Singapore - 049315, Tel: +65 62322451 and email: navneet_babbar@icicisecuritiesinc.com, Rishi_agrawal@icicisecuritiesinc.com.
"In case of eligible investors based in Japan, charges for brokerage services on execution of transactions do not in substance constitute charge for research reports and no charges are levied for providing research reports to such investors."

New l-Sec investment ratings (all ratings based on absolute return; All ratings and target price refers to 12-month performance horizon, unless mentioned otherwise) BUY: >15\% return; ADD: 5\% to 15\% return; HOLD: Negative 5\% to Positive 5\% return; REDUCE: Negative 5\% to Negative 15\% return; SELL: < negative 15\% return

## ANALYST CERTIFICATION

I/We, Aniruddha Joshi, CA; Nilesh Patil, MBA; authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of the ICICI Securities Inc. It is also confirmed that above mentioned Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months and do not serve as an officer, director or employee of the companies mentioned in the report.
Terms \& conditions and other disclosures:
ICICI Securities Limited (ICICI Securities) is a full-service, integrated investment banking and is, inter alia, engaged in the business of stock brokering and distribution of financial products. Registered Office Address: ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025. CIN: L67120MH1995PLC086241, Tel: (91 22) 6807 7100. ICICI Securities is Sebi registered stock broker, merchant banker, investment adviser, portfolio manager, Research Analyst and Alternative Investment Fund. ICICI Securities is registered with Insurance Regulatory Development Authority of India Limited (IRDAI) as a composite corporate agent and with PFRDA as a Point of Presence. ICICI Securities Limited Research Analyst SEBI Registration Number - INH000000990. ICICI Securities Limited SEBI Registration is INZ000183631 for stock broker. ICICI Securities AIF Trust's SEBI Registration number is IN/AIF3/23-24/1292 ICICI Securities is a subsidiary of ICICI Bank which is India's largest private sector bank and has its various subsidiaries engaged in businesses of housing finance, asset management, life insurance, general insurance, venture capital fund management, etc. ("associates"), the details in respect of which are available on www.icicibank.com.
ICICI Securities is one of the leading merchant bankers/ underwriters of securities and participate in virtually all securities trading markets in India. We and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Investment Research Department. ICICI Securities and its analysts, persons reporting to analysts and their relatives are generally prohibited from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.
Recommendation in reports based on technical and derivative analysis centre on studying charts of a stock's price movement, outstanding positions, trading volume etc as opposed to focusing on a company's fundamentals and, as such, may not match with the recommendation in fundamental reports. Investors may visit icicidirect.com to view the Fundamental and Technical Research Reports.
Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein.
ICICI Securities Limited has two independent equity research groups: Institutional Research and Retail Research. This report has been prepared by the Institutional Research. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the Retail Research.
The information and opinions in this report have been prepared by ICICI Securities and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of ICICI Securities. While we would endeavour to update the information herein on a reasonable basis, ICICI Securities is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent ICICI Securities from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or ICICI Securities policies, in circumstances where ICICI Securities might be acting in an advisory capacity to this company, or in certain other circumstances. This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. ICICI Securities will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. ICICI Securities accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice.
ICICl Securities or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.
ICICI Securities or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction.
 from the companies mentioned in the report in the past twelve months.
ICICI Securities encourages independence in research report preparation and strives to minimize conflict in preparation of research report. ICICI Securities or its associates or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither ICICI Securities nor Research Analysts and their relatives have any material conflict of interest at the time of publication of this report.
Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.
ICICI Securities or its subsidiaries collectively or Research Analysts or their relatives do not own $1 \%$ or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the publication of the research report.
Since associates of ICICI Securities and ICICI Securities as a entity are engaged in various financial service businesses, they might have financial interests or actual/ beneficial ownership of one percent or more or other material conflict of interest in various companies including the subject company/companies mentioned in this report.
ICICI Securities may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.
Neither the Research Analysts nor ICICI Securities have been engaged in market making activity for the companies mentioned in the report.
We submit that no material disciplinary action has been taken on ICICI Securities by any Regulatory Authority impacting Equity Research Analysis activities.
This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject ICICI Securities and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.
This report has not been prepared by ICICI Securities, Inc. However, ICICI Securities, Inc. has reviewed the report and, in so far as it includes current or historical information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. None of the research recommendations promise or guarantee any assured, minimum or risk free return to the investors
Name of the Compliance officer (Research Analyst): Mr. Atul Agrawal, Contact number: 022-40701000, E-mail Address : complianceofficer@icicisecurities.com For any queries or grievances: Mr. Prabodh Avadhoot Email address: headservicequality@icicidirect.com Contact Number: 18601231122


[^0]:    Source: Company data, I-Sec research

[^1]:    Source: Company data, I-Sec research

[^2]:    Source: Company data, I-Sec research

[^3]:    Source: Bloomberg, I-Sec research

[^4]:    Source Company data, I-Sec research

